Prioritised projects are the endocrine treatment using Estetrol (E4) and a new immunotherapy Zona Pellucida (ZP). Both projects are ready for out-licensing.
Estetrol is a fetal estrogen suitable for oncological applications including breast cancer (BC) and prostate cancer (PC). At present phase II clinical studies have successfully achieved proof-of-concept. High Dose E4 (HDE4) has demonstrated promising anti-tumor activity and major improvement of quality of life in breast and prostate cancer patients (dual efficacy). The project is ready for phase IIB (BC) and phase III (PC) studies. Pantarhei is potentially interested in (pharmaceutical) partners for the further development of HDE4.
Zona Pellucida refers to a new cancer treatment by immunisation against the specific antigen Zona Pellucida 3 (ZP3). The ZP3 program opens a promising way to discover a new immunotherapy for several cancers, including ovarian cancer, prostate cancer, colorectal cancer and (non-small cell) lung cancer. Proof-of-principle has been obtained in pre-clinical studies. The project is in final pre-clinical development and is available for out-licensing of all indications.